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Abstract  
 
Background: Results of previous research have identified the need for further investigation 
into the compliance with good practice guidelines for current decision-analytic modelling 
(DAM). 
 
Objective: To identify the extent to which recent model-based economic evaluations of 
interventions focused on lowering the blood pressure (BP) of patients with hypertension 
conform to published guidelines for DAM in healthcare using a five-dimension framework 
developed to assess compliance to DAM guidelines. 
 
Methods: A systematic review of English language articles was undertaken to identify 
published model-based economic evaluations that examined interventions aimed at lowering 
BP. The review covered the period January 2000 to March 2015 and included the following 
electronic bibliographic databases: EMBASE and Medline via Ovid interface and the Centre 
for Reviews and Dissemination’s (CRD) NHS-EED. Data were extracted based on different 
components of good practice across five dimensions utilizing a framework to assess 
compliance to DAM guidelines.  
 
Results: Thirteen papers were included in this review. The review found limited compliance 
to good practice DAM guidelines which was most frequently justified by the lack of data.  
 
Conclusions: The assessment of structural uncertainty cannot yet be considered common 
practice in primary prevention and management of hypertension and researchers seem to face 
difficulties with identifying sources of structural uncertainty and then handling them 
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correctly. Additional guidelines are needed to aid researchers in identifying and managing 
sources of potential structural uncertainty. Adherence to guidelines is not always possible and 
it does pose challenges, in particular when there are limitations due to data availability that 
restrict, for example, a validation process. 
 
Words: 254 
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Introduction 
Cardiovascular disease (CVD), which incorporates coronary heart disease (CHD) and stroke, 
is the main cause of death worldwide
1
 and in England and Wales.
2
 Hypertension, defined as a 
persistent raised blood pressure (BP) of 140/90 mmHg,
3
 has been recognised as the most 
important modifiable risk factor for CVD.
2, 3
 Poorly controlled high BP can damage artery 
walls and increase the risk of developing a blood clot. Moreover, if it is not treated it can also 
damage organs such as the kidneys, heart and brain. Decision-analytic modelling (DAM) 
guidelines have recognised that randomised controlled clinical trials (RCTs) are good sources 
of evidence to judge the effectiveness of treatments; however, because the time horizon for 
trials often does not reflect the full duration of the impact of interventions, DAM is used to 
extend the results of a short term trial over a longer time horizon.
4, 5
 A primary outcome used 
in RCTs that are focused on hypertension is often change in BP. However, this is only an 
intermediate outcome and DAM can be used to examine the impact of change in BP on the 
risk of CVD events in the longer term.  
Previous research has identified the need for further investigation into the compliance of 
DAM to good practice and its impact on the conclusions drawn from economic evaluations.
6
 
Our aim is to critically evaluate how DAM in primary prevention of CVD conforms to 
guidelines and, in doing so, validate a framework previously developed to assess compliance 
to guidelines. The focus here is on one particular clinical area since this makes it possible to 
remove some of the variation between models which is not relevant for the purpose of 
assessing compliance (for example, different outcomes, treatment options or sources of 
uncertainty). CVD prevention has been selected due to the wide number of recent and 
available model-based cost-effectiveness (CE) studies conducted in this topic area. We 
focused on interventions aimed at lowering BP, as a modifiable risk factor for CVD, and 
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sought to answer the research question: ‘to what extent do model-based economic evaluations 
of primary prevention interventions aimed at lowering BP in patients with hypertension or at 
risk of developing hypertension conform to the published guidelines for DAM?’  
 
Methods 
Studies of interventions aimed at lowering BP were reviewed and the challenges faced when 
applying DAM methods were identified and discussed. A systematic review was conducted, 
meeting the UK Centre for Review and Dissemination guidance and the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines for reporting.
7
  
The review followed a structured approach for framing research questions: patient population 
(P), intervention (I), the comparator group (C), outcome (O) and the study design (S), or 
PICOS.
7
 Papers published from January 2000 to March 2015 and written in English were 
included in this review if they met all of the following conditions:  
 the target population was individuals presenting with high BP or at risk of developing 
hypertension;  
 the intervention(s) aimed at lowering BP;  
 management of hypertension, as a modifiable risk factor for CVD, was part of a 
primary prevention strategy (when studies also included secondary prevention, we 
have concentrated on the results for primary prevention); and  
 the study was a model-based economic evaluation.  
This review excluded systematic reviews, guidelines, trials, protocols and conference 
abstracts. In addition, we also excluded studies where the interventions: 
 were aimed at screening BP; 
A systematic review of applied DAM studies 
 
7 
 
 were part of a polypill strategy;  
 measured non-adherence to treatment; or 
 were part of a secondary prevention and treatment strategy. 
 
Searches were undertaken using terms identified by expert clinical opinion and a list of 
synonyms identified for each term that helped inform the final search terms used in this 
review (“cost effectiveness”, “mathematical model”, “decision analysis”, “Markov model”, 
“decision tree”, “economic evaluation”, “hypertension” and “lowering blood pressure”). The 
search was undertaken using truncations and wildcards and all synonyms were subsequently 
combined with appropriate medical subject heading terms (MeSH) or subject terms using 
Boolean operators (Appendices 1 and 2). 
The following databases were searched: EMBASE and Medline via the Ovid interface, and 
the Centre for Reviews and Dissemination’s (CRD) NHS Economic Evaluation Database 
(NHS-EED). In addition, we manually examined the reference lists of the studies included in 
this review. All papers identified by database searching were exported into ENDNOTE-X7
TM
 
and duplicate references were removed. 
Titles identified by the searches were screened by reading the abstract; this activity was 
completed by two reviewers (SJ and CP). Articles that appeared to be relevant at this point 
were obtained and screened against the inclusion and exclusion criteria (CP); several papers 
appeared relevant on reading the abstract but were subsequently excluded after reading the 
full paper.  
All studies were manually searched and data were extracted by a single reviewer (CP); any 
doubtful point(s) were checked with at least one another reviewer.
6
 The extraction tool 
consisted of a framework
6
 that synthesizes contemporary DAM guidelines in a single 
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checklist instrument; this framework was developed to aid researchers assessing adherence to 
guidelines. The tool aided the retrieval and organisation of information from each study 
across five dimensions (Appendix 3): 
i) problem concept; 
ii) model concept; 
iii) synthesis of evidence;  
iv) analysis of uncertainty; and  
v) model transparency and validation. 
This approach ensured that the review did not miss any information related to the model 
building process. Data were extracted as free text and in the form of a ‘yes/no’ response. 
 
Results 
The database search yielded 2607 studies; after removing 27 duplicates, 2580 studies were 
left for screening. 2549 studies were excluded because they did not consider a CVD related 
intervention, were not a model-based economic evaluation, or were focused on screening 
(Figure 1). 31 full-text articles were assessed for eligibility, of which 18 were rejected as a 
secondary prevention strategy. 13 studies were included in this review, none of which were 
identified through other sources (Figure 1).  
Only two of the studies included were published prior to 2004. Thus it can be seen that the 
majority of studies (11/13) would have had access to DAM guidelines at the time of their 
publication (for example, Weinstein (2003)
8
 or Philips (2004)
9
).  
Four studies evaluated programmes for the clinical prevention and treatment of 
hypertension
10-13
 and nine evaluated antihypertensive drug treatments to lower BP (Table 
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1).
14-22
 Ten studies were cost-utility analyses (CUA) or combined both CUA and a cost-
effectiveness analysis (CEA)
10-12, 15-17, 19-22
 while three studies were CEA
13, 14, 18
 (Table 1). 
The intervention target (risk factor) examined was high BP. The remainder of this section 
describes the main findings.  
 
Problem concept and model concept 
The decision problem and study objective(s) were stated in all the studies (Table 2), and all 
evaluated CE from a health care payer perspective. The target decision-maker audience was 
made explicit in 10/13 studies as that of the health care payer, i.e. including only the health 
effects experienced by patients receiving the intervention and costs for the medical services 
required to provide the intervention.
23
 For the remaining studies
10, 14, 19
 the perspective was 
left implicit. Ekman
19
 commented that the analysis was “in a Swedish health-care setting”, 
while Stevanovic
14
 was interested “in the Dutch setting” and Gandjour10 focused on those 
“insured by the German SHI”, where SHI refers to the German Statutory Health Insurance. 
For all studies, the target population was individuals with hypertension or at risk of 
developing hypertension (Tables 1 and 2), frequently stratified by gender, presence of 
hypertension, age groups, and mean age. The target population was always modelled as 
closed (reflecting members entering only at the start of the analysis). 
Despite all the studies sharing a common aim, namely primary prevention of CVD via 
lowering BP, these economic models compared a wide range of interventions and presented 
their results using outcome measures such as QALYs,
10-12, 15-17, 19-22
 life years gained 
(LYG),
13, 14, 16, 18, 20, 22
 net health benefits (NHB),
18
 net monetary benefits (NMB)
17
 and 
expected value of perfect information (EVPI)
17
 (Table 1).  
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Side effects were modelled in only one study.
15
 Four studies
10, 11, 14, 22
 acknowledged the lack 
of adverse events as a limitation of their results due to lack of data. Two studies argued that 
since ‘previous clinical trials found that first-line hypertensive drugs do not have more side 
effects than placebo’13 or they have ‘mild side effects’19 there was no need to model adverse 
effects. Similarly another study argued that fatal side effects would have been already 
captured in the clinical trials via the measure of effectiveness.
18
   
All the studies commented on the reasons for the selection of their comparators, where their 
choice of comparators seems to have been governed by the scope of the study. Two studies 
acknowledged as a limitation the exclusion of relevant comparator(s) arguing that there may 
be more relevant comparators not included.
19, 21
 Furthermore, the ‘do nothing’ option was 
considered in four of the studies.
10, 14, 18, 19
 
All the studies used Markov models and included a figure showing the model structure; in 
one study
13
 the structure of the Markov model shown in the figure did not seem to reflect the 
structure of the model described in the text. The model structures accounted for both acute 
and chronic health states. Five studies made explicit reference to how the structure of their 
models was defined either by using an existing generic model,
18
 being based on disease 
progression
10, 11
 or consisting of health states designed to reflect the course and history of 
CVD events.
22
 One study reported that ‘health states in the Markov model are based on 
cardiovascular events measured in the previously reported registry study’.21 For the 
remaining studies it was inferred that the model structure was based on disease progression. 
A lifetime time horizon was adopted in all but two studies: of these, one used a five-year
15
 
time horizon for a population aged 65 years whilst the second used 20-years for a population 
aged 18 and over.
22
 The five-year time horizon was justified as matching the five-year time 
span given to social security authorities in China for budget planning
15
 whilst the 20-year 
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time horizon was not discussed.
22
 Cycle length, though rarely justified in the studies, was 
always 1 year. Only one study
10
 justified their choice as most of the data used in their model 
referred to a 1-year period.  
 
Synthesis of evidence 
Patient heterogeneity was considered in most of the studies; results were presented by age 
cohorts
10, 12, 14, 15, 18
 and gender.
10-12, 14-16, 18, 19, 21
 Some studies added further analyses based on 
the risk of CVD,
10, 12, 17
 scenarios of SBP reduction
14, 19
 smoking
14
 and patient adherence.
14, 22
 
The risks of secondary events were modelled in seven of the studies - e.g. the risk of a further 
stroke after a first stroke-.
12-14, 18-21
 In some instances, assumptions were acknowledged; for 
example, the study by Stevanovic
14 
assumed the risk of secondary events to be equal to the 
risk of a first non-fatal CVD event. The authors acknowledged that this would lead to an 
under-estimation of the CVD risk, and so an increased risk of death in patients experiencing 
non-fatal CVD events was adopted.
14 
 In Wisloff,
18
 secondary non-fatal events were allowed, 
and a patient experiencing a secondary event was assumed to be in a health state which was 
worse than the state they were already in. For example, a patient with stroke sequelae that 
experiences a MI will have the risk and costs associated with the stroke sequelae and not 
those related to MI). Perman
13
 utilized expert opinion in the assessment of the risk of 
secondary events. Montgomery,
12
 due to a lack of data assumed that any second 
cardiovascular event was fatal and acknowledged this as a limitation. Some studies that did 
not use separate states to model secondary events
10, 11, 22
 captured the increased mortality 
from secondary events through the mortality rate of patients surviving CVD events. Few of 
the studies acknowledged the lack of epidemiological data to model secondary events as a 
limitation.
11, 22
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All studies applied discounting to their results: a discount rate of 3% was most common for 
costs and benefits;
10, 15, 17, 19, 21, 22
 two studies used a different discount rate for costs and 
benefits (Stevanovic used 4% and 1.5%
14
 while Montgomery used 6% and 1.5%
12
 
respectively) (Table 1). Information on the parameters used as inputs were most frequently 
presented in tables showing mean values and the type of distribution(s) while some studies 
also included 95% confidence intervals or range intervals.
10, 11, 20
 The methods used to report 
the sources of information varied from reporting a detailed list of sources per parameter in a 
table to mentioning the sources of data in the main text.  
 
Analysis of uncertainty 
The studies examined and reported uncertainty surrounding their identified outcomes through 
sensitivity analysis (SA). Uncertainty in parameter estimates was most commonly handled 
through deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA). 
Five studies used only one-way DSA,
12, 15, 19, 20, 22
 whilst another four
11, 16-18
 only used PSA. 
Only one study measured EVPI
17
 (Table 2).    
Elements pertaining to structural uncertainty (SU) were acknowledged as such in six 
studies.
10, 11, 13, 14, 19, 20
 Most commonly SU was assessed through SA by varying the time 
horizon,
11
 the duration of the effectiveness of the treatment,
11, 14
 the discount rate
13, 19
 or by 
using alternative measures of outcomes.
19
 One study examined the impact of assumptions 
related to secondary events.
18
 Lack of clinical evidence for key parameters such as the 
treatment effect of drugs
10, 11, 14
 was identified as a source of SU. Two studies acknowledged 
that they could have included more relevant comparators had they had more information,
19, 21
 
and another two acknowledged that they had excluded a potentially relevant state due to lack 
of epidemiological data
10
 or insufficient evidence on its relevance.
20
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The decision about which events and health states were included was partially discussed. 
Some studies acknowledged that they subdivided a health state
11
 (CHD into MI, HF and 
angina), or excluded a potentially relevant health state
15
 (combined stroke and MI event). All 
studies included chronic health states (post events); however, few discussed having modelled 
the progression of disease.
10, 11, 22
 Most frequently, the studies acknowledged the adoption of 
assumptions, i.e. assuming the duration of treatment effects to be lifetime or as long as the 
time horizon in the model,
10, 11, 14
 or five years
19
 or varied.
21
 
 
Model transparency and validation 
All the studies included a graphical description of the Markov model they used (Table 2). 
Sources of funding were identified in 11 studies: five were funded by the pharmaceutical 
industry,
14-16, 19, 21, 22
 one benefited from joint funds from government and pharmaceutical 
sources, 
18
 three were exclusively government-funded,
11, 12, 20
 and one was privately funded.
17
 
None of the studies stated any means for accessing more detailed information about the 
model. All the studies had a clear policy context with an explicit statement of funder and 
developer.  
Validation, according to guidelines,
24
 is a set of methods for judging the accuracy of a model 
in making relevant predictions, in other words, validation helps readers understand what a 
model does and how it does it. In this review we checked for five main types of validation. 
All the studies were subjected to face validity checks (having been peer reviewed and 
published in a journal) and they were subjected to verification (internal validity checking). 
The methods used were justified to a greater or lesser extent in each study. All studies 
undertook SA of parameters as a way to double check that the direction and magnitude of 
their outputs were as expected.  
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In terms of cross validation, results were mixed. Eight studies
10-14, 17, 19, 20
 examined different 
models that addressed the same problem and compared their results; however the level of 
detail provided varied. Five studies presented limited or no evidence of cross-validation;
15, 16, 
18, 21, 22
 only Wisloff
18
 undertook an exercise of external validation by comparing their 
estimated lifetimes to those reported by Statistics Norway and in doing so they found that the 
input into their model needed to be adjusted to fit Norwegian mortality data. An assessment 
of predictive validity was not included in any of the studies considered. 
 
Discussion 
Using a previously developed practical framework,
6
 we have critically evaluated how 13 
published economic evaluations conformed to contemporaneous good practice guidelines. 
We found that published economic evaluations of interventions aimed at lowering BP in 
patients with hypertension, as part of a primary prevention strategy of CVD, demonstrate 
limited compliance to DAM guidelines which has usually been explained by lack of data or 
imperfect data. This was particularly apparent in the assessment of SU (or lack of) and model 
external validation.  
This review identified common grounds in terms of the adherence to, and use of, guidelines. 
The conceptual modelling in all the studies included in this review was based on a disease 
process where the focus was on the definition of the health states (conditions) as opposed to 
treatment (pathways) received and where the decision problem posed required the evaluation 
of the reduction in the risk of developing hypertension, thus explaining the use of Markov 
models. 
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It has been argued that alternative model structures can lead to variations in model 
predictions,
25
 most importantly, in the context of a primary prevention strategy, an 
inappropriate model structure may lead to poorly informed policy decisions, resulting in 
inefficient allocation of scarce resources.
26
 Models are by nature sensitive to choices made at 
every single stage during the model development process (i.e., model concept, model 
structure). There will almost always be more than one set of choices, for this reason, 
guidelines have suggested assessing the extent to which model predictions are influenced by 
the choices made during the model development process, and have suggested methods to do 
so, such as scenario analyses.
27, 28
  
Lifetime time horizons should be adopted (or be justified when constrained by the cohort’s 
lifetime) or at the very least, time horizons should be ‘long enough’ to capture relevant 
differences in outcomes across strategies.
23
  Lack of data or imperfect data still poses 
important challenges for researchers - for example, when modelling the risk of secondary 
events and disease progression or to attempt the assessment of model validity -. Even though 
elements pertaining to SU were identified by various authors, the assessment of SU cannot be 
considered common practice in this particular clinical area and additional guidelines are still 
needed to aid researchers identifying and quantifying SU.  
External validity still poses a challenge to researchers and more importantly, to future 
guidelines due to the apparent unavailability of actual extra data (from RCT or patient level 
data) to undertake the exercise. It has been suggested that instead of using all the data 
available to create a model, some data be set aside to use during the validation process (for 
example, one-third of the data).
29
 This may or may not always be possible, and will depend 
on how much data a researcher has to build a model.  
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Studies included in this review shared similar research questions and yet there was a great 
diversity in the structures of the Markov models used. Some of these were simple and some 
more complex,  and they were generally developed with limited justification.
26
 These 
indicate, as suggested by Squires, et al (2016),
30
 that the methods for the development of the 
model structure are still underdeveloped. This can lead to errors including poor validity, 
credibility, and no basis for model verification and the analysis of structural uncertainty. 
Caro and Möller
29
 described the above as the disposable approach to modelling: models are 
built for a single use, focused on a particular product for a relatively short time. This explains 
- to some extent - the reduced motivation for undertaking model validation.
29
 Future research 
should examine whether the development of ‘generic models’, or, as proposed by Caro and 
Möller, the development of multi-use models over time, can capture sufficient detail to be 
realistic and avoid particulars for which there are no data, and thereby allow the economic 
evaluation of interventions targeting CVD in any setting, and whether this will bridge the 
knowledge gap and, most importantly, allow ease of comparison between the results obtained 
from different studies.  
This is the first study that has critically reviewed compliance to DAM guidelines using a 
previously developed practical framework. It has covered more than a decade of published 
DAM studies of interventions aimed at lowering BP in patients with hypertension. We 
believe the inclusion of recent studies from European, American and Asian countries has 
helped to reflect current practice worldwide.  
The exclusion criteria adopted may be considered as limitation; however, these were required 
to guarantee consistency in the analysis. Furthermore, a negligible number of non-English-
language studies were identified pertaining to applied studies. The fact that none of the 
studies included was published after the release of the ‘five-dimension framework’ and the 
A systematic review of applied DAM studies 
 
17 
 
selection of one particular clinical area (and any impact on generalisability this may have) 
may also be considered a limitation. 
Our findings seem in line with recent debate around the methodological challenges being 
faced by DAM where model validation and SU have been identified as fundamental problems 
due to the lack of motivation, time and data to validate models and, in the case of SU, a lack 
of methods.
29
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Table 1 Summary of analytic framework, methods and model features of studies included 
Study/  
Year 
Research 
Question 
Perspective/  
Country 
Comparators 
Target  
Population/ 
Intervention 
Time 
Horizon/ 
Discount 
Rate 
Reported 
Baseline 
Results 
Health 
States 
Study 
Design and 
Outcomes  
Kaambwa  
et al,  
2014 
11
 
LT CE of self-
management of 
HPN 
UK NHS  Self-management of 
HPN versus usual 
care 
66-year old  
with HPN 
Lifetime; 
3.5% for 
both 
Self-management of HPN 
was CE  
ICER £1,624/QALY  
Well              
Stroke               
MI         
Angina       
HF 
Death       
CUA                                                 
QALYs 
Stevanovic  
et al, 2014
14
 
CE of lowering 
BP in patients 
with HPN and 
low CVD risk 
Dutch HIS Anti-HPN with 
HCTZ versus various 
combinations of 
HCTZ/Losartan 
(ACEIs) or 
HCTZ/ARBs versus  
no-treatment  
Various age 
groups: 40, 50, 
60 and 65, 
gender and 
various HPN 
groups  
10 year 
and 
lifetime; 
4 % for 
costs and 
1.5 % for 
health 
Systolic BP reduction was 
found CE 
A 65-year old:  
-10 year lifetime: 
HCT €6,032/LYG man or 
€12,345/LYG woman; 
-Lifetime: 
HCT €3,076/LYG man or 
€3,074/LYG woman 
Disease free-
HPN Acute 
CVD (non-
fatal)    
Stable CVD 
(non-fatal)    
Fatal CVD    
Non-CVD 
death 
CEA                                         
LYG                                        
Wu  
et al, 2013 
15
 
CE of 
Amlodipine 
(CCB) versus 
ARB in the 
prevention of 
stroke and MI 
Chinese Third 
party payer 
Amlodipine (CCB) 
versus ARB 
Average 65-year 
old cohort 
presenting HPN 
5 years, 
3% for 
both 
Amlodipine was the 
dominant strategy 
Disease free-
HPN 
Stroke         
Post-stroke    
MI            
Post-MI      
Dead 
CUA                                         
QALYs 
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Kourlaba  
et al, 2013
16
 
CE of a BP 
lowering drug 
therapy in 
patients with 
mild-to-
moderate HPN 
Greek Third 
party payer 
Telmisartan /HCTZ 
compared to 
Losartan/HCTZ and 
Valsartan/HCTZ  
Average 57-year 
old cohort 
presenting HPN; 
analyses 
undertaken by 
gender 
Lifetime, 
3.5% for 
both 
Telmisartan found to be 
CE 
Males: 
€3,002/QALY or 
€1,765/LYG 
Females: 
€10,856/QALY or 
€7,076/LYG 
Disease free-
HPN Non-
fatal MI              
post- non-
fatal MI   
Stroke        
Post-stroke    
death 
CEA                                         
CUA                                         
LYG                                  
QALYs 
Ekwunife  
et al, 2013 
17
 
CE of drugs in 
the management 
of HPN 
Nigerian third 
party payer 
perspective for 
costs 
4 classes of 
antihypertensive 
medications: HCTZ, 
pranolol (Beta 
Blocker), lisinopril 
(ACE) and nifedipine 
(CCB) 
Average 40-year 
olds with HPN  
30 years; 
3% for 
both 
In the low CVRS ACEI 
had highest  (15,000 
$/QALY) NMB, however 
in the medium and high 
risk CVRSs, CCB had 
highest WTP (15,000 and 
12,500 $/QALY 
respectively) 
Non-
asymptomati
c (disease 
free)      
Stroke        
Non-fatal 
Stroke  CHD            
non-fatal 
CHD 
CUA                                         
NMB                                         
EVPI                                      
US$/ 
QALYs 
Wisloff  
et al,  
2012 
18
 
CE of various 
generic anti-
HPN in the 
prevention of 
CVD 
Norwegian 
HIS  
CCB compared to no-
treatment in various 
age groups and 
gender 
HPN patients at 
different age 
groups (40, 50, 
60 and 70) 
Lifetime, 
4% for 
both 
CCB / male was CE: 
40: -€456,838/LYG 
50: -€445,018/LYG 
60: -€410,510/LYG 
70: -€352,875/LYG 
CCB /female was CE: 
40: -€621,537/LYG 
50: -€630,144/LYG 
60: -€588,999/LYG 
70: -€465,906/LYG 
Disease free-
HPN Stroke         
Stroke-
Sequelae 
AMI             
Angina         
HF           
Post-CVD    
Dead             
CEA                                         
LYG                                       
NHB  
Baker et al, 
2012 
22
 
CE of initiating 
hypertension 
treatment with 
valsartan and 
then switching 
to generic 
losartan in the 
prevention of 
CVD 
US third party 
payer 
perspective 
Two comparative 
analyses: 
1.Continual Valsartan 
vs continual Losartan 
2.Continual Valsartan 
vs Valsartan switch 
to generic Losartan 
Moderate HPN 
patients – SBP 
160-179-  aged 
18 and older  
20-year 
time 
horizon 
and 3% 
discount 
for both 
Treatment of moderate 
hypertension was 
considered CE with an 
ICER of $32,313/QALY 
or $27,268/LYG; 
Switching treatment 
resulted in an ICER of 
£30,170/QALY and 
$25,460/LYG 
CVD event 
free with 
treated HPN 
Post-CVD 
with treated 
HPN 
Death 
CVD event 
rates per arm 
CEA 
CUA 
LYG 
QALYs 
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Granstrom  
et al, 
2012 
21
 
Long-term CE 
of Candesartan 
versus Losartan 
in the primary 
prevention of 
HPN 
Swedish HIS Candesartan versus 
Losartan  
Average 62-year 
old cohort 
presenting with 
HPN 
Lifetime, 
3% for 
both 
Candesartan was the 
dominant strategy 
Disease free-
HPN HF              
Chronic IHD  
Post-MI       
PAD            
Post-stroke  
Arrhythmia   
Dead 
CUA                                         
QALYs 
Perman  
et al,  
2011 
13
 
CE multi-
intervention 
programme 
versus 
pharmacological 
strategy 
Argentinian 
Third party 
payer  
HPN programme 
compared to  usual 
care  
Two target 
groups: 65-year 
old plus HPN; 
65-year old, 
HPN and 
previous CVD 
Lifetime, 
5% for 
both 
The HPN programme was 
cost-effective 
US$1,124/LYG 
Acute 
myocardial 
event       No 
event    
Death 
CEA                                           
LYG 
Ekman  
et al,  
2008 
19
 
CE of Irbesartan 
in combination 
with HCTZ in 
BP reduction 
Swedish third 
party payer  
Four strategies in 
male and female 
population: 
Irbesartan 
Placebo 
Losartan 
Valsartan 
55-year old 
male cohort 
presenting with 
HPN 
Lifetime; 
3% for 
both 
Irbesartan was CE when 
compared to placebo in 
males and females; ICERs 
of €3,451/QALY and 
€7,704/QALY respectively 
Losartan & Valsartan were 
dominated by Irbesartan in 
males and females 
Disease free-
HPN Angina        
MI            
Post-MI  
CHF  Stroke       
Post-Stroke       
Dead 
CUA                                         
QALYs 
Gandjour  
et al, 
2007 
10
 
CE of a national 
HPN 
programme for 
patients with 
essential HPN 
and without 
CVD  
German HIS National programme  
versus no programme 
(for low and high risk 
population) 
Various age 
groups  
(40-49, 50-59, 
and 60-69); 
patients with 
essential HPN 
and without 
CVD 
Lifetime; 
3% for 
both 
National programme is CE  
High risk male, 
40: €800/QALY, 
50: €880/QALY 
60: €757/QALY 
High risk female, 
40: -€17,347/QALY 
50: -€26,987/QALY 
60: -€1,263/ QALY 
 
Disease free-
HPN MI                    
Stroke               
Renal- 
failure      
death 
CUA                                             
QALYs 
Montgomery et Effectiveness UK Health Anti HPN treatment Various pop Lifetime; Treatment found more CE Untreated CUA                                         
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al, 2003 
12
 and CE of LT 
BP lowering  
service 
perspective 
versus non-treatment  cohorts: 30-39; 
40-49; 50-59; 
60-69; 70-79. 
Hypertensive 
population 
6% for 
costs and 
1.5% for 
effects 
than non-treatment. ICER 
was higher for low risk 
women compared to low 
risk men 
Treated T_se 
U_cve_ua 
T_cve_ua 
T_se_cve_ua 
U_cve_af 
T_cve_af 
T_se_cve_af  
Death 
 
QALYs 
Nordmann  
et al,  
2003 
20
 
CE of ACE as 
HPN first-line 
therapy versus 
conventional 
therapy  
Canadian 
Third party 
payer  
4 strategies: 
-Control or 
conventional therapy 
-ECG  
- EchoCar  
-ACE  
40-year old 
male cohort 
presenting with 
HPN but 
without CVD 
Lifetime; 
5% for 
both 
 
Unfavourable results of 
CE: 
ECG versus Control: US$ 
0 /QALY/LYG;  
EchoCar vs Control: US$ 
200,000/QALY/LYG  
ACE vs Control = 
US$700,000/QALY or 
US$525,000/LYG 
Disease free-
HPN (with 
or without 
LVH)           
CAD            
CVD            
CHF            
Dead 
CEA             
CUA                                        
LYG                                       
QALYs 
 
 
List of abbreviations: 
 
 
ACE   = Angiotensin-Converting-Enzyme Inhibitor 
AMI                = Acute Myocardial Infarction 
ARB   = Angiotensin-II-Receptor Blocker 
BP   = Blood pressure 
CCB   = Calcium-Channel Blocker 
CE   = cost-effectiveness or cost-effective 
CEA   = Cost-effectiveness analysis 
CHF   = Congestive Heart Failure 
CUA   = Cost-utility analysis 
CVD   = Cardiovascular disease 
EchoCar  = Echocardiography 
EVPI  = Expected Value of Perfect Information 
HCTZ   = Hydrochlorothiazide 
HF   = Heart Failure 
HIS   = Health Insurance System 
HPN   = Hypertension 
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IHD   = Ischaemic Heart Disease 
LYG   = Life Year Gained 
MI          = Myocardial infarction  
NHB   = Net Health Benefit 
NMB  = Net Monetary Benefit 
LT   = Long term 
PAD   = Peripheral Artery Disease 
T_se  = Treated, side-effects (health state) 
U_cve_ua = Untreated, cardiovascular event, unaffected (health state) 
T_cve_ua = Treated, cardiovascular event, unaffected (health state) 
T_se_cve_ua  = Treated, side-effects, cardiovascular event, unaffected (health state) 
U_cve_af = Untreated, cardiovascular event, affected (health state) 
T_cve_af = Treated, cardiovascular event, affected (health state) 
T_se_cve_af  = Treated, side-effect, cardiovascular event, affected (health state) 
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Table 2 Adherence to good practice guidelines – summary results of assessment 
 
Dimension 1 Problem concept 
 
 
Information Review question Kaambwa et 
al, 2014 
Stevanovic et 
al, 2014 Wu et al, 2013 
Kourlaba et al, 
2013 
Ekwunife et 
al, 2013 
Wisloff  et al, 
2012 
Decision 
problem 
Is there a written decision problem? 
Yes Yes Yes Yes Yes Yes 
Are the study’s objective(s) consistent with the 
decision problem and the study’s scope? 
Yes Yes Yes Yes Yes Yes 
Analytical 
perspective 
Has the perspective being stated? 
Yes Yes Yes Yes Yes Yes 
Target 
population 
Has the target population being identified? 
Yes Yes Yes Yes Yes Yes 
Health 
outcomes 
Are model’s outcome(s) consistent with the 
perspective, scope and model’s objective(s)?  Yes Yes Yes Yes Yes Yes 
Have any adverse effect(s) be captured? 
No No Yes No No No 
Interventions 
modelled 
Are the options under evaluation clear?  
Yes Yes Yes Yes Yes Yes 
Were the inclusion/ exclusion of feasible options 
justified? Yes Yes Yes Yes Yes Yes 
Time horizon 
Is it sufficient to reflect all important differences 
between options? Yes Yes No Yes Yes Yes 
Have time horizon, duration of the treatment and 
the treatment effect(s) described and justified? Yes Yes No Yes Yes Yes 
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Continuation 
Information Review question 
Baker et al, 
2012 
22
 
Granstrom et 
al, 2012 
Perman G et 
al, 2011 
Ekman et al, 
2008 
Gandjour et 
al, 2007 
Montgomery 
et al, 2003 
Nordmann 
A.J et al, 
2003 
Decision 
problem 
Is there a written decision problem? 
Yes Yes Yes Yes Yes Yes Yes 
Are the study’s objective(s) consistent with 
the decision problem and the study’s scope? 
Yes Yes Yes Yes Yes Yes Yes 
Analytical 
perspective 
Has the perspective being stated? 
Yes Yes Yes Yes Yes Yes Yes 
Target 
population 
Has the target population being identified? 
Yes Yes Yes Yes Yes Yes Yes 
Health 
outcomes 
Are model’s outcome(s) consistent with the 
perspective, scope and model’s objective(s)?  
Yes Yes Yes Yes Yes Yes Yes 
Have any adverse effect(s) be captured? 
No No No No No No No 
Interventions 
modelled 
Are the options under evaluation clear?  
Yes Yes Yes Yes Yes Yes Yes 
Were the inclusion/ exclusion of feasible 
options justified? 
Yes Yes Yes Yes Yes Yes Yes 
Time horizon 
Is it sufficient to reflect all important 
differences between options? 
Yes Yes Yes Yes Yes Yes Yes 
Have time horizon, duration of the treatment 
and the treatment effect(s) described and 
justified? 
Yes 
Yes Yes Yes Yes Yes Yes 
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Dimension 2 Model concept 
 
Information Review question Kaambwa et al, 
2014 
Stevanovic et al, 
2014 
Wu et al, 
2013 
Kourlaba et al, 
2013 
Ekwunife et al, 
2013 
Wisloff  et 
al, 2012 
Choice of 
model type 
Was the unit of representation given?  Yes Yes Yes Yes Yes Yes 
Does interaction(s) among individuals need to be 
model? If yes, was this described? 
No No No No No No 
Does the decision problem require a short time 
horizon? 
No No No No No No 
Is it necessary to model time in discrete cycles?  Yes Yes Yes Yes Yes Yes 
Was a type of model discussed and chosen?  Yes Yes Yes Yes Yes Yes 
Model 
structure 
Was the starting cohort defined by demographic 
and clinical characteristics affecting transition 
probabilities or state values?  
Yes Yes Yes Yes Yes Yes 
Were health states and transitions reflecting the 
biological or theoretical understanding of the 
disease modelled? 
Yes Yes Yes Yes Yes Yes 
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Continuation 
Information Review question 
Baker et al, 
2012 
22
 
Granstrom et 
al, 2012 
Perman et al, 
2011 
Ekman et 
al, 2008 
Gandjour et 
al, 2007 
Montgomery 
et al, 2003 
Nordmann 
et al, 2003 
Choice of 
model type 
Was the unit of representation given?  
Yes Yes Yes Yes Yes Yes Yes 
Does interaction(s) among individuals need 
to be model? If yes, was this described? 
No No No No No No No 
Does the decision problem require a short 
time horizon? 
No No No No No No No 
Is it necessary to model time in discrete 
cycles?  
Yes Yes Yes Yes Yes Yes Yes 
Was a type of model discussed and chosen?  
Yes Yes Yes Yes Yes Yes Yes 
Model 
structure 
Was the starting cohort defined by 
demographic and clinical characteristics 
affecting transition probabilities or state 
values?  
Yes Yes Yes Yes Yes Yes Yes 
Were health states and transitions reflecting 
the biological or theoretical understanding of 
the disease modelled? 
Yes Yes Yes Yes Yes Yes Yes 
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Dimension 3 Synthesis of evidence 
 
Information Review question  Kaambwa et 
al, 2014 
Stevanovic et 
al, 2014 
Wu et al, 
2013 
Kourlaba et 
al, 2013 
Ekwunife et 
al, 2013 
Wisloff 
et al, 
2012 
Patient heterogeneity  Was patient heterogeneity required/considered? Yes Yes Yes Yes Yes Yes 
Data sources 
Were transition probabilities and intervention effects derived 
from representative data sources?  
Yes Yes Yes Yes Yes Yes 
Were (all) methods and assumptions used to derive the 
model's inputs described? 
Yes Yes Yes Yes Yes Yes 
Were parameters derived from observational studies 
controlled for confounding?  
NA NA NA NA NA NA 
Was data's quality discussed? Yes Yes No Yes Yes Yes 
If expert opinion was used, were its methods described and 
justified? 
No NA NA NA NA Yes 
Utilities (HSUV- 
weights & benefits)  
Are the utilities incorporated into the model appropriate?  Yes NA Yes Yes Yes NA 
Is the source for the utility weights referenced? Yes NA Yes Yes Yes NA 
Half cycle correction Was the use of a half cycle correction stated? Yes No No No No No 
Resources including 
costs 
Were the costs used in the model justified and its sources 
described? 
Yes Yes Yes Yes Yes Yes 
Were discount rates reported and justified? Yes Yes Yes Yes Yes Yes 
Communicating 
results 
Did the report presented results using non-technical language 
aided by figures or tables? 
Yes Yes Yes Yes Yes Yes 
Parameter precision 
Were mean value(s), distribution(s), source(s) of data and 
rationale for the supporting evidence described? 
Yes Yes No Yes Yes Yes 
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Continuation 
 
Information Review question  
Baker et 
al, 2012 
22
 
Granstrom 
et al, 2012 
Perman et 
al, 2011 
Ekman 
et al, 
2008 
Gandjour 
et al, 
2007 
Montgomery 
et al, 2003 
Nordmann 
et al, 2003 
Patient 
heterogeneity  
Was patient heterogeneity required/considered? 
No Yes No Yes Yes Yes Yes 
Data sources 
Were transition probabilities and intervention effects 
derived from representative data sources?  
Yes Yes Yes Yes Yes Yes Yes 
Were (all) methods and assumptions used to derive the 
model's inputs described? 
Yes Yes Yes Yes Yes Yes Yes 
Were parameters derived from observational studies 
controlled for confounding?  
NA Yes NA NA NA Yes NA 
Was data's quality discussed? 
Yes Yes Yes Yes Yes Yes Yes 
If expert opinion was used, were its methods described 
and justified? 
NA NA NA NA No NA Yes 
Utilities (HSUV- 
weights & 
benefits)  
Are the utilities incorporated into the model 
appropriate?  
Yes Yes NA Yes Yes Yes Yes 
Is the source for the utility weights referenced? 
Yes Yes NA Yes Yes Yes Yes 
Half cycle 
correction 
Was the use of a half cycle correction stated? 
No Yes No No Yes No Yes 
Resources 
including costs 
Were the costs used in the model justified and its 
sources described? 
Yes Yes Yes Yes Yes Yes Yes 
Were discount rates reported and justified? 
Yes Yes Yes Yes Yes Yes Yes 
Communicating 
results 
Did the report presented results using non-technical 
language aided by figures or tables? 
Yes Yes Yes Yes Yes Yes Yes 
Parameter 
precision 
Were mean value(s), distribution(s), source(s) of data 
and rationale for the supporting evidence described? 
Yes Yes Yes Yes Yes No No 
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Dimension 4 Analysis of uncertainty 
 
Information Review question  Kaambwa et 
al, 2014 
Stevanovic et 
al, 2014 
Wu et al, 
2013 
Kourlaba et 
al, 2013 
Ekwunife et 
al, 2013 
Wisloff et 
al, 2012 
Analysis of 
uncertainty  
Was analysis of uncertainty pertaining to the decision 
problem included and reported? 
Yes Yes Yes Yes Yes Yes 
Parameter 
estimation & 
uncertainty 
Were one-way or two-way DSA sensitivity analysis 
performed? 
No Yes Yes No No No 
Was a probabilistic sensitivity analysis (PSA) included? Yes Yes No Yes Yes Yes 
Multivariate 
estimation and 
correlation 
Was correlation among parameters considered? NA NA NA NA NA NA 
Structural 
uncertainty 
Were there any discussion /evidence of uncertainty in 
structural assumptions? 
Yes Yes No No No Yes 
Other reporting of 
uncertainty 
analyses 
Was EVPI measured/ discussed? No No No No Yes No 
If model calibration was used to estimate parameters, was 
uncertainty tested?  
NA NA NA NA NA NA 
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Continuation 
 
Information Review question  
Baker et al, 
2012 
22
 
Granstrom 
et al, 2012 
Perman et al, 
2011 
Ekman 
et al, 
2008 
Gandjour 
et al, 2007 
Montgomery 
et al, 2003 
Nordmann 
et al, 2003 
Analysis of 
uncertainty  
Was analysis of uncertainty pertaining to the 
decision problem included and reported? 
Yes Yes Yes Yes Yes Yes Yes 
Parameter 
estimation & 
uncertainty 
Were one-way or two-way DSA sensitivity analysis 
performed? 
Yes Yes Yes Yes Yes Yes Yes 
Was a probabilistic sensitivity analysis (PSA) 
included? 
No Yes Yes No Yes No No 
Multivariate 
estimation and 
correlation 
Was correlation among parameters considered? 
NA NA NA NA NA NA NA 
Structural 
uncertainty 
Were there any discussion /evidence of uncertainty 
in structural assumptions? 
No No Yes Yes Yes No Yes 
Other reporting 
of uncertainty 
analyses 
Was EVPI measured/ discussed? 
No No No No No No No 
If model calibration was used to estimate parameters, 
was uncertainty tested?  
NA NA NA NA NA NA NA 
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Dimension 5 Model transparency and validation 
 
Information Review question Kaambwa et 
al, 2014 
Stevanovic et 
al, 2014 
Wu et al, 
2013 
Kourlaba et 
al, 2013 
Ekwunife et 
al, 2013 
Wisloff et 
al, 2012 
Transparency  
Were the purpose, type and graphical description of the 
model provided? 
Yes Yes Yes Yes Yes Yes 
Were the source(s) of funding and their role identified? Yes Yes Yes Yes Yes Yes 
Were data sources identified/ described? Yes Yes Yes Yes Yes Yes 
Were methods customised to specific application(s) and 
settings? 
Yes Yes Yes Yes Yes Yes 
Were the effects of uncertainty measured? Yes Yes Yes Yes Yes Yes 
Were limitations acknowledged/ discussed? Yes Yes Yes Yes Yes Yes 
Was any reference to the availability of model's 
documentation at request or terms and conditions to 
access it? 
No No No No No No 
Validation 
Was there any evidence of model’s face validity? Yes Yes Yes Yes Yes Yes 
Was internal validity (verification or technical validity) 
assessed? 
Yes Yes Yes Yes Yes Yes 
Was cross-validation (external consistency) assessed? Yes Yes No Yes Yes No 
Was external validity assessed  No Yes No No No No 
Was the model’s predictive validity assessed? NA NA NA NA NA NA 
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Continuation 
 
Information Review question 
Baker et al, 
2012 
22
 
Granstrom 
et al, 2012 
Perman et al, 
2011 
Ekman et 
al, 2008 
Gandjour 
et al, 2007 
Montgomery 
et al, 2003 
Nordmann  
et al, 2003 
Transparency  
Were the purpose, type and graphical description 
of the model provided? 
Yes Yes Yes Yes Yes Yes Yes 
Were the source(s) of funding and their role 
identified? 
Yes Yes No Yes No Yes Yes 
Were data sources identified/ described? 
Yes Yes Yes Yes Yes Yes Yes 
Were methods customised to specific 
application(s) and settings? 
Yes Yes Yes Yes Yes Yes Yes 
Were the effects of uncertainty measured? 
Yes Yes Yes Yes Yes Yes Yes 
Were limitations acknowledged/ discussed? 
Yes Yes Yes Yes Yes Yes Yes 
Was any reference to the availability of model's 
documentation at request or terms and conditions 
to access it? 
No No No No No No No 
Validation 
Was there any evidence of model’s face validity? 
Yes Yes Yes Yes Yes Yes Yes 
Was internal validity (verification or technical 
validity) assessed? 
Yes Yes Yes Yes Yes Yes No 
Was cross-validation (external consistency) 
assessed? 
No No Yes Yes Yes Yes Yes 
Was external validity assessed  
No No No No No No No 
Was the model’s predictive validity assessed? 
NA NA NA NA NA NA NA 
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SUPPLEMENTAL MATERIAL 
 
Appendix 1 
Search strategy: Cochrane databases (searched 20 March 2015 14:00:51,676 for the period 2000 to 2015)  
NHS EED (economic evaluations) 
 
ID Searches - CRD (NHS-EED) 
#1 MeSH blood pressure EXPLODE PERMUTE  
#2 MeSH hypertension EXPLODE PERMUTE 
#3 cost utility analys*  
#4 mathematical model  
#5 decision analys*  
#6 Markov chain* or Markov process* or decision tree  
#7 Economics 
#8 cost effective* or cost effective* analys*  
#9 #3 OR #4 OR #5 OR #6 OR #7 OR #8 
#10 #1 OR #2  
#11 #9 AND #10 
#12 MeSH primary prevention EXPLODE PERMUTE  
#13 #11 AND #12 
NHS EED National Health Service Economic Evaluation Database, */$ wildcard characters 
A systematic review of applied DAM studies 
 
35 
 
 
Appendix 2 
EMBASE and MEDLINE databases (searched 20 March 2015 16:59) via OVID MEDLINE(R)  
ID 
Searches (via OVID) 
#1 (lowering blood pressure or lowering-blood-pressure or blood pressure lowering).mp. 
[mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]  
#2 (hypertensi$ or antihypertensi$ or anti-hypertensi$).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
dv, kw, nm, kf, px, rx, an, ui]  
#3 1 OR 2 
#4 (cost effective$ OR cost-effective$ OR mathematical model OR decision-analys$s OR 
decision analys$s OR Markov OR decision tree OR economic evaluation OR cost 
utility).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, an, ui]  
#5 3 AND 4 
#6 limit 5 to English language 
#7 limit 6 to yr="2000 -Current" 
#8 limit 7 to humans 
#9 Exclude conference abstracts, methodological papers, commentaries, editorials, notes 
#10 remove duplicates from 9 
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Appendix 3 Framework to assess adherence to good practice guidelines in Decision-Analytic Modelling 
(DAM) 
Source: Peñaloza et al. A Systematic Review of Research Guidelines in Decision-Analytic Modeling. Value in 
Health 18 (2015), Table 5, p. 524-527.  
DIMENSION 1: PROBLEM CONCEPT 
Components 
of good 
practice 
Questions for 
review 
Yes 
, 
No, 
or 
NA 
Attributes 
Decision 
problem  
Is there a written 
statement of the 
decision problem and 
scope of the study?  
  
A clear statement of the decision problem and scope would determine 
the interventions and health outcomes to be measured 
Are the objective(s) of 
the study and model 
structure consistent 
with the stated decision 
problem and scope? 
  
They are expected to be consistent 
 
Analytical 
perspective 
Has the perspective of 
the model been stated?   
Most common perspectives are: patient, health system (insurer) and 
society 
Target 
population 
Has the target 
population been 
identified? 
  
Target population should be defined in terms of features relevant to the 
decision (geography, patient characteristics, including comorbid 
conditions, disease prevalence and stage) 
Health 
outcomes 
Are the outcomes of the 
model stated and 
consistent with the 
perspective, scope and 
overall objective(s) of 
the model?  
  
Health outcomes may be events, cases of disease, deaths, life-years 
gained, quality-adjusted life-years, disability-adjusted life-years or other 
measures important to stakeholders and should be directly relevant to 
the question being asked 
Has any adverse effect 
of the intervention(s) 
been captured? 
  
Interventions may cause negative health consequences that need to be 
modelled and discussed as part of the study's results. The impact of 
assumptions regarding adverse effects of interventions should be 
assessed as part of the structural uncertainty analysis 
Comparators 
Is there a clear 
definition of the 
alternative interventions 
under evaluation? 
  
Usually the choice of comparators is governed by the scope of the model. 
Impact of assumptions adopted when deciding upon comparators should 
be assessed as part of the structural uncertainty analysis 
Is there a discussion 
around feasible options 
or justification for the 
exclusion of feasible 
options? 
  
The choice of comparators affects results and should be determined by 
the decision problem, not by data availability. All feasible and practical 
strategies as determined by the scope of the model should be 
considered. Constraining the range of strategies should be justified 
Time 
horizon 
Is the time horizon of 
the model justified and 
sufficient to reflect all 
important differences 
between options? 
  
Time horizon of the model should be long enough to capture relevant 
differences in outcomes across strategies (lifetime). Time horizon is 
dictated by the problem scope 
 Note: NA= Not Apply 
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DIMENSION 2: MODEL CONCEPT 
Components 
of good 
practice 
Questions for 
review 
Yes 
, 
No, 
or 
NA 
Attributes 
Choice of 
model type 
Has the unit of 
representation been 
given?  
  
Usually stated in terms of groups or individuals. If groups are being 
modelled most frequently decision trees, Markov processes or infectious 
disease models are the correct choice; if individuals are being modelled 
then the choice is between DES, dynamic transmission models or agent-
based models 
Is there a need to model 
the interaction between 
individuals in this model? 
Has this been discussed? 
  
If interactions between individuals is required (when the disease or 
treatment includes interactions between individuals) then DES, dynamic-
transmission, or agent-based models may be the correct choice 
Does the decision problem 
require a short time 
horizon? 
  
For simple models or problems (short time horizon, few outcomes) a 
decision tree may be appropriate; time horizon should be large enough to 
capture all health effects and costs directed related to the decision 
problem 
Is it necessary to model 
time in discrete cycles?    
Continuously for Individual STM  or in discrete cycles for Markov STM;  if 
the assumption that transition probabilities do not depend on history is 
not required, then individual state-transition models are an alternative; If 
disease or treatment process need to be represented as health states, 
state transition models are appropriate (Markov type) 
Is there a need to model 
competition for resources 
or the development of 
waiting lists or queues? 
  
 If the problem requires the ability of a model to incorporate interactions 
between individuals and other model parts for example to answer 
questions on resource allocation i.e., organ allocation for transplantation, 
distribution of antiretroviral medications in resource-poor environments, 
then a DES may be appropriate 
Has a type of model been 
chosen and discussed?     
It is expected that studies report on the reasons for choosing a type of 
model 
Model 
structure 
Has the starting cohort 
been defined by 
demographic and clinical 
characteristics affecting 
the transition probabilities 
or state values?  
  
If results may vary by subgroups (age, sex, risk factors) is advisable to 
report results for different cohorts 
Has health states and 
transitions reflecting the 
biological/theoretical 
understanding of the 
disease or condition been 
modelled? 
  
States should adequately capture the type of intervention (prevention, 
screening, diagnostics, and treatment) as well as the intervention's 
benefits and harms. States need to be homogeneous with respect to both 
observed and unobserved characteristics that affect transition 
probabilities 
Note: NA= Not Apply 
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DIMENSION 3: SYNTHESIS OF EVIDENCE 
Components 
of good 
practice 
Questions for review 
Yes, 
No, 
or 
NA 
Attributes 
Data sources 
Has transition probabilities and 
intervention effects been 
derived from representative 
data sources for the decision 
problem? 
  
Most common sources of data include population-based 
epidemiological studies, control arms of trials or literature 
Has (all) methods and 
assumptions used to derive 
transition probabilities and 
intervention effects been 
described/justified? 
  
Attention should be given to the use of transition probabilities 
and rates; conversion of transition probabilities from one time 
unit to another should be done through rates and never 
presented as percentages 
Has parameters relating to the 
effectiveness of interventions 
derived from observational 
studies been controlled for 
confounding?  
  
If results of meta-analyses were used as data sources then 
consider how potential confounders are addressed; consider 
the likelihood of increased heterogeneity resulting from 
residual confounding and from other biases across studies. 
Efficacy derived from RCT may have to be adjusted for 
compliance to reflect real-world effectiveness. Effectiveness 
derived from observational studies must be adjusted for 
confounding (e.g., using multivariate regression techniques or 
propensity scoring). Adjustment for time-varying confounding 
(confounders that simultaneously act as intermediate steps in 
the pathway between intervention and outcome) require 
special methods such as marginal structural analysis or g-
estimation. When results from observational studies are used 
in the model, causal graphs can be used to explicitly state 
causal assumptions 
Has the quality of the data been 
assessed appropriately?   
Sources of data and data limitations are expected to be 
discussed 
Has expert opinion been used, 
are the methods described and 
justified? 
  
An expectation that strengths and limitations of assumptions 
adopted should be included 
Utilities  
Are the utilities incorporated 
into the model appropriate?    
methods used to obtain utility weights and methodology used 
to transform health estate estimates into quality of life scores 
Is the source for the utility 
weights referenced?   
Sources of data and data limitations are expected to be 
discussed 
Cycle length 
and half cycle 
correction 
Has the choice of cycle length 
been justified?   
It should be based on the clinical problem and remaining life 
expectancy 
Has the use of a half cycle 
correction been stated?   Any assumption adopted is expected to be disclosed 
Resources/ 
costs 
Are the costs incorporated into 
the model justified and sources 
described? 
  
Sources of data and data limitations are expected to be 
discussed Has discount rates been 
reported and justified given the 
target decision-maker? 
  
Patient 
heterogeneity  
Has patient heterogeneity been 
considered?   
For example, in a cohort model states need to be homogeneous 
to observed or unobserved characteristics affecting transition 
probabilities to observed or unobserved characteristics 
affecting transition probabilities 
Parameter 
precision 
Has mean values and 
distributions around the mean 
and the source and rationale for 
the supporting evidence been 
clearly described for each 
parameter included in the 
model? 
  
Sources of data and data limitations are expected to be 
discussed 
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DIMENSION 4: ANALYSIS OF MODEL UNCERTAINTY 
Components 
of good 
practice 
Questions for 
review 
Yes 
, 
No, 
or 
NA 
Attributes 
Uncertainty  
Has analyses of 
uncertainty pertaining 
to the decision problem 
been included and 
reported? If not, has 
the reasons been 
explained for its 
omission? 
  Analysis of uncertainty is expected to be include as part of the DAM 
Parameter 
estimation 
& 
uncertainty 
Has one-way DSA or 
two-way sensitivity 
analysis been 
performed? 
  
Tornado diagrams, threshold plots or simple statements of threshold 
parameter values, are all appropriate. Uncertainty of parameters may be 
represented by several discrete values, instead of a continuous range, 
called 'scenario analyses'. It is a good practice to include the specification of 
parameter’s point estimate and a 95% CI range.  
Has a Probabilistic 
Sensitivity Analysis 
(PSA) been included? 
  
The specific distribution (e.g. Beta, normal, lognormal) as well as its 
parameters should be disclosed. When PSA is performed without an 
accompanying EVPI, options for presenting results include CEAC and 
distributions of net monetary benefit or net health benefit. When more 
than two comparators are involved, curves for each comparator should be 
plotted on the same graph. 
Has correlation among 
parameters been 
assessed? 
  
Lack of evidence on correlation among parameters should not lead to an 
assumption of independence among parameters 
If model calibration was 
used to derive 
parameters, has the 
uncertainty around 
calibrated values been 
tested using DSA or 
PSA?  
  
Calibration is commonly used to estimate parameters or adjust estimated 
values such as overall and disease specific mortality and event incidence 
rates 
Structural 
uncertainty 
Has a discussion about 
the inclusion/exclusion 
of assumptions 
affecting the structure 
of the model been 
included?  
(refers to potentially 
relevant comparators, 
health states and 
recurrent events or any 
other assumption 
affecting the structure 
of the model)  
  
For example: i) health states and the strategies adopted following the 
recurrence of events; ii) length of treatment effects; iii) types of adverse 
effects included; iv) duration of treatment effects; v) time dependency of 
probabilities (in a time dependent utility, the cost of delaying treatment as 
a function of the time a patient has remained in an untreated acute 
pathological state); vi) prognostic implications of surrogate end points; vii) 
clinical events; viii) comparators. Although these structural assumptions are 
not typically quantified, it is uncertain whether they express reality 
accurately and for that reason they should be assessed as part of structural 
uncertainty analysis 
Other 
reporting of 
uncertainty 
analyses 
Has the EVPI being 
measured /discussed?   
If the purpose of a PSA is to guide decisions about acquisition of 
information to reduce uncertainty in the results, EVPI should be presented 
in terms of expected value of information. EVPI is commonly reported in 
monetary terms using net monetary benefit or net health benefits; EVPI 
should be reported for specified ICER thresholds 
Note: NA= Not Apply 
DIMENSION 5: MODEL TRANSPARENCY AND VALIDATION 
Components 
of good 
Questions for 
review 
Yes 
, 
Attributes 
A systematic review of applied DAM studies 
 
40 
 
practice No, 
or 
NA 
Transparency  
Has a graphical description 
of the model been 
provided? 
  
  
Has all sources of funding 
and their role been 
identified? 
  
  
Has all methods used been 
customised to specific 
application(s) and settings? 
  
  
Has the report used 
nontechnical language and 
clear figures and tables to 
enhance the understanding 
of the model? 
  
  
Has limitations and 
strengths been 
acknowledged/discussed? 
  
  
Is there any reference as to 
whether technical 
documentation would be 
made available at request? 
  
  
Validation 
Is there any evidence of 
model’s face validity?   
Can occur in several ways: the group that develop the model can 
appeal to members of the modelling group, people in the same 
organisation who did not build the model, or external consultants. 
Any reader can perform his/her own evaluation. Peer review 
(previous to publication) 
Has internal validity been 
assessed?   
Verification or technical validity; models should be subject to 
rigorous verification and the methods used should be described and 
results made available on request 
Has cross-validation been 
assessed?   
or external consistency (involves examining different models that 
address the same problem and comparing their results) its 
meaningfulness depends on the degree to which methods and data 
are independent. Modellers should search for modelling analyses of 
the same or similar problems and discuss insights gained from 
similarities and differences in results 
Has external validity been 
assessed?    
This compares the model's results with actual event data; a formal 
process needs to be developed including identifying suitable sources 
of data; results of external validation should be made available 
Has the model’s predictive 
validity been assessed?   If feasible given the decision problem and future's sources availability 
Note: NA= Not Apply 
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